Temasek completes 10.16% stake purchase in Intas Pharma

Singapore government's investment arm Temasek Holding has completed the acquisition of 10.16 per cent stake in Indian company Intas Pharmaceuticals.
Temasek acquired the stake by way of secondary purchase of shares from private equity investor ChrysCapital.
This investment will deepen Temasek's exposure to the country's pharma industry.
"ChrysCapital has been a valuable partner for Intas over the years. We are delighted to have lived up to the expectation of ChrysCapital and now look forward to welcoming Temasek to enable Intas to reach greater heights in the years to come," Intas Vice Chairman and Managing Director of Binish Chudgar today said in a statement.

"Intas has been an excellent investment for ChrysCapital with the company having grown revenues at 27 per cent CAGR since its investment in CY06... ChrysCapital reaffirmed its faith in the Company with a fresh Rs 300 crore investment from a separate fund in CY12 and will continue to remain invested for the next few years," ChrysCapital MD Sanjiv Kaul said.
Intas, incorporated in India, is a vertically integrated pharmaceutical company with global operations. The company has presence in more than 70 countries in North America, Europe, Central and Latin America, Africa, Australia, New Zealand and Asia-Pacific.
Last month, Competition Commission of India (CCI) had approved Temasek's proposed 10.16 per cent stake purchase in Intas.